Please wait while the formulary information is being retrieved.
ARIKAYCE (amikacin sulfate liposomal with nebulizer accessories)
- Refractory mycobacterium avium complex pulmonary disease
590 mg/8.4 mL suspension for inhalation via nebulization
- Inhale 8.4 milliliters (590 mg) via nebulizer by inhalation route once daily
Refractory mycobacterium avium complex pulmonary disease
- Inhale 8.4 milliliters (590 mg) via nebulizer by inhalation route once daily
- typhoid vaccine
- Vivotif Berna Vaccine
Contraindicated
- BCG live
- BCG vaccine, live (PF)
- Tice Bcg
Severe
Moderate
- ampicillin sodium
- ampicillin-sulbactam
- Bicillin C-r
- Bicillin L-a
- Cedax
- cefaclor
- cefadroxil
- cefazolin
- cefazolin in dextrose (iso-os)
- cefdinir
- cefepime
- cefepime in dextrose 5 %
- cefepime in dextrose,iso-osm
- cefotaxime
- cefotetan
- cefotetan in dextrose, iso-osm
- cefoxitin
- cefoxitin in dextrose 3.9 %
- cefoxitin in dextrose, iso-osm
- cefpodoxime
- cefprozil
- ceftazidime
- ceftazidime in D5W
- ceftazidime-dextrose (iso-osm)
- ceftibuten
- Ceftin
- ceftriaxone
- ceftriaxone in dextrose,iso-os
- cefuroxime axetil
- cefuroxime in sterile water
- cefuroxime sodium
- cefuroxime-dextrose (iso-osm)
- cephalexin
- Claforan
- Fortaz
- Fortaz In Dextrose 5 %
- Keflex
- Maxipime
- Mefoxin In Dextrose (iso-osm)
- nafcillin
- nafcillin in dextrose iso-osm
- oxacillin
- oxacillin in dextrose(iso-osm)
- penicillin G benzathine
- penicillin G benzathine & proc
- penicillin G pot in dextrose
- penicillin G potassium
- penicillin G procaine
- penicillin G sodium
- Pfizerpen-g
- piperacillin-tazobactam
- piperacillin-tazobactam-dextrs
- Rocephin
- Tazicef
- ticarcillin-clavulanate
- Timentin
- Unasyn
- Zinacef
- Zinacef In Sterile Water
- Zosyn
- Zosyn In Dextrose (iso-osm)
- None
Contraindicated
- Chronic obstructive pulmonary disease
- Disorder of the 8th cranial nerve
- Kidney disease with reduction in GFR
- Myasthenia gravis
- Parkinsonism
- Tinnitus
Severe
Moderate
- None
ARIKAYCE (amikacin sulfate liposomal with nebulizer accessories)
- Refractory mycobacterium avium complex pulmonary disease
- Bronchospastic pulmonary disease
- Hemoptysis
- Ototoxicity
- Cough
- Diarrhea
- Fatigue
- General weakness
- Musculoskeletal pain
- Nausea
- Voice change
More Frequent
Severe
Less Severe
- COPD exacerbation
- Hypersensitivity pneumonitis
- Pneumonia
- Pneumothorax
- Ataxia
- Chest discomfort
- Dysgeusia
- Epistaxis
- Fever
- Headache disorder
- Increased sputum
- Laryngitis
- Oral candidiasis
- Pain in oropharynx
- Pharyngeal edema
- Pharyngitis
- Skin rash
- Symptoms of anxiety
- Vomiting
- Weight loss
- Xerostomia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Nephrotoxicity
- Neuromuscular blockade
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Amikacin liposome (inhalation)
No pediatric safety and efficacy established.
- 1 Day – 18 Years
- No pediatric safety and efficacy established.
Amikacin (inh)
- Severity Level:
2
- Additional Notes: Systemic absorption is likely to be low after oral inhalation
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
Amikacin
Trace amounts excreted, poor oral absorption
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Excreted | Not known; no or inclusive data | Trace amounts excreted, poor oral absorption |
Contraindicated
None
Precaution Exists
Amikacin (liposomal, Inhaled)
General-No overall differences in safety and effectiveness have been observed between elderly subjects and younger subjects. Renal-Liposomal inhaled amikacin has not been studied in patients with renal impairment. Given the low systemic exposure to amikacin following administration, clinically relevant accumulation of amikacin is unlikely to occur in patients with renal impairment. However, renal function should be monitored in patients with known or suspected renal impairment.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- Amikacin liposomal may increase the risk of serious breathing or lung problems. Tell your doctor right away if you have symptoms such as new or worsening shortness of breath/trouble breathing, fever, cough, wheezing, or coughing up blood or blood-tinged sputum.
| Refractory mycobacterium avium complex pulmonary disease | |
| A31 | Infection due to other mycobacteria |
| A31.0 | Pulmonary mycobacterial infection |
| A31.9 | Mycobacterial infection, unspecified |
| 0-9 | A-Z |
|---|---|
| A31 | Infection due to other mycobacteria |
| A31.0 | Pulmonary mycobacterial infection |
| A31.9 | Mycobacterial infection, unspecified |
Formulary Reference Tool